In a report released yesterday, Charlie CY Yang from Bank of America Securities reiterated a Buy rating on Royalty Pharma (RPRX – Research ...

BofA analyst Charlie Yang raised the firm’s price target on Royalty Pharma (RPRX) to $39 from $38 and keeps a Buy rating on the shares. The ...

UBS has recently reduced Royalty Pharma plc (RPRX) stock to Neutral rating, as announced on June 3, 2024, according to Finviz. Earlier, on June 14, 2022, UBS had resumed the stock to Buy, setting a ...

Atria Investments Inc trimmed its stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 15.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and ...

On Thursday, Royalty Pharma plc (RPRX) stock saw a decline, ending the day at $25.58 which represents a decrease of $-0.27 or -1.04% from the prior close of $25.85. The stock opened at $25.9 and ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or organizations who positively impact healthcare, was awarded to Micheal Milken. The prize ...

The market shrugged off Royalty Pharma plc's ( NASDAQ:RPRX ) solid earnings report. We think that investors might ...

A U.S. jury on Tuesday awarded $42 million to three former detainees of Iraq's notorious Abu Ghraib prison, holding a ...

A U.S. jury has awarded $42 million to three former detainees of Iraq’s notorious Abu Ghraib prison, holding a Virginia-based ...